Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

Woerdenbag, Herman J.; Olinga, Peter; Kok, Ellen A.; Brugman, Donald A. P.; Ark, Ulrike F. van; Ramcharan, Arwin S.; Lebbink, Paul W.; Hoogwater, Frederik J.H.; Knapen, Daan G; Groot, Derk Jan A. de; Nijkamp, Maarten W.

doi:10.3390/cancers15072119

Cited by 11 publications

(2 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of CBD/THC in cancer patients primarily focus on reducing symptom distress, including cancer-related pain, cachexia, nausea, and vomiting. However, conflicting results have been reported in clinical trials, and findings may lack statistical power [ 222 , 223 , 224 , 225 ]. A recent retrospective chart review suggested that there was no statistically significant change in symptom distress with medical cannabis use in cancer patients [ 226 , 227 ].…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…There are a lot of studies that describe cannabinoids impact on pain management, Parkinson's disease, spasticity due to multiple sclerosis or paraplegia, epilepsy, ophthalmological diseases, or different kinds of psychiatric disorders [8][9][10][11][12][13][14][15][16]. In recent years, interest in the potential therapeutic properties of CBD in the treatment of cardiovascular [17], cancer [18], metabolic [19], and neurodegenerative [20] diseases has increased.…”

Section: Introductionmentioning

confidence: 99%

The Use of Cannabidiol in Metabolic Syndrome—An Opportunity to Improve the Patient’s Health or Much Ado about Nothing?

Wiciński,

Fajkiel-Madajczyk,

Kurant

et al. 2023

JCM

View full text Add to dashboard Cite

Cannabis-derived therapies are gaining popularity in the medical world. More and more perfect forms of cannabinoids are sought, which could be used in the treatment of many common diseases, including metabolic syndrome, whose occurrence is also increasing. The purpose of this review was to investigate the usefulness of cannabinoids, mainly cannabidiol (CBD), in individuals with obesity, impaired glucose and lipid metabolism, high blood pressure, and non-alcoholic fatty liver disease (NAFLD). We summarised the most recent research on the broad topic of cannabis-derived influence on metabolic syndrome components. Since there is a lot of work on the effects of Δ9-THC (Δ9-tetrahydrocannabinol) on metabolism and far less on cannabidiol, we felt it needed to be sorted out and summarised in this review. The research results on the use of cannabidiol in obesity are contraindicatory. When it comes to glucose homeostasis, it appears that CBD maintains it, sensitises adipose tissue to insulin, and reduces fasting glucose levels, so it seems to be a potential target in this kind of metabolic disorder, but some research results are inconclusive. CBD shows some promising results in the treatment of various lipid disorders. Some studies have proven its positive effect by decreasing LDL and increasing HDL as well. Despite their probable efficacy, CBD and its derivatives will likely remain an adjunctive treatment rather than a mainstay of therapy. Studies have also shown that CBD in patients with hypertension has positive effects, even though the hypotensive properties of cannabidiol are small. However, CBD can be used to prevent blood pressure surges, stabilise them, and have a protective effect on blood vessels. Results from preclinical studies have shown that the effect of cannabidiol on NAFLD may be potentially beneficial in the treatment of the metabolic syndrome and its components. Nevertheless, there is limited data on CBD and NAFLD in human studies. Because of the numerous confounding factors, the conclusions are unclear, and more research in this field is required.

show abstract

Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI‐Designated Cancer Center

Baral,

Diggs,

Marrakchi El Fellah

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveThis study aims to describe patterns, sources, and reasons for cannabis use among cancer patients during active treatment (+CDTX) compared to no‐use during active treatment (−CDTX).MethodsData are from 385 surveys collected via REDCap during phase I of an ongoing study among adult cancer patients seen at an NCI‐designated comprehensive cancer center within the last 5 years of treatment. A harmonized survey was created with 11 other NCI centers to assess cannabis use patterns, sources, and reasons for use. Sociodemographics and cancer details were also collected via self‐report. Descriptive statistics were calculated and stratified by +/−CDTX. Chi‐squared tests were conducted to compare proportions between groups.ResultsAmong the sample [49.5 years (SD 15.9); 53.0% male; and 41.6% Hispanic/Latino], 41.0% + CDTX and 59.0% −CDTX. A majority (71.8%) of +CDTX initiated use before diagnosis versus 44.1% in −CDTX (p < 0.0001); patients diagnosed with stage 4 cancer had a statistically significant higher prevalence of +CDTX (60.0%; p = 0.003); 53.3% in radiation reported +CDTX compared to 42.8% in chemotherapy, and 36.4% in immunotherapy. Dispensaries and local dealers were the top sources of cannabis in both groups. Among +CDTX, 44.3% consumed cannabis at least once a day DTX, dominant cannabinoids used were CBD (35.2%), Delta‐8‐THC (18.3%), and CBD + THC ratio (14.1%); 12.7% were unsure what they consumed. Joints were the most common inhalation method (61.5%), and store‐bought candy was the most common edible (39.2%). Depression/mood, pain, and enjoyment were the top three reasons for +CDTX compared to enjoyment, depression/mood, and nausea/upset stomach in −CDTX (p = 0.02).ConclusionsPatterns, sources, and reasons for cannabis use varied between +CDTX and ‐CDTX. Future studies should examine the impacts of cannabis and specific cannabinoids on cancer treatment, drug interactions, survival outcomes, and quality of life.

show abstract

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

Cited by 11 publications

References 145 publications

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

The Use of Cannabidiol in Metabolic Syndrome—An Opportunity to Improve the Patient’s Health or Much Ado about Nothing?

Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI‐Designated Cancer Center

Contact Info

Product

Resources

About